We therefore sought to determine whether circulating levels of MMPs and TIMPs in a new, larger cohort of cardiac amyloidosis patients would allow us to differentiate between patients with AL‐CMP and those with TTR‐CMP and perhaps aid in further clinical management. The gene discussed is TTR; the disease is axial length measurement.